RecruitingPhase 1NCT07195916

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Sponsor

Incyte Corporation

Enrollment

280 participants

Start Date

Jan 8, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumors Hematologic Malignancies

Summary

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new drug called INCA036873 in people with advanced cancers — specifically clear cell kidney cancer, certain types of B-cell lymphoma, T-cell lymphoma, or cutaneous T-cell lymphoma — that have progressed after standard treatments. **You may be eligible if...** - You are 18 or older with a histologically confirmed diagnosis of one of the eligible cancers (clear cell renal cell carcinoma, DLBCL, high-grade B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma at stage IIB or above) - Your cancer has progressed or is refractory to the required number of prior treatments (varies by cancer type) - Your general health score (ECOG) is 0 or 1 - You have measurable disease by standard imaging criteria and tumor tissue available for testing **You may NOT be eligible if...** - You have untreated or active brain metastases - Your cancer type is not one of the eligible subtypes - You have not received the required prior treatments - Your health or organ function does not meet the required thresholds Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA036873

Intravenously (IV)

Locations(22)

City of Hope Medical Center

Duarte, California, United States

University of California San Diego Medical Center, Moores Cancer Center

La Jolla, California, United States

University of Michigan

Ann Arbor, Michigan, United States

The University of Nebraska Medical Center

Omaha, Nebraska, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Scri Oncology Partners

Nashville, Tennessee, United States

Vanderbilt Medical Center

Nashville, Tennessee, United States

Md Anderson Cancer Center

Houston, Texas, United States

Macquarie University Hospital

Sydney, New South Wales, Australia

Princess Alexandra Hospital Australia

Woolloongabba, Queensland, Australia

Cancer Research Sa

Adelaide, South Australia, Australia

Peter Maccallum Cancer Centre-Royal Melbourne Hospital

Melbourne, Victoria, Australia

Cliniques Universitaires Ucl Saint-Luc

Brussels, Belgium

Universitair Ziekenhuis Antwerpen

Edegem, Belgium

Universitair Ziekenhuis Gent (Uz Gent)

Ghent, Belgium

Universitair Ziekenhuis Leuven

Leuven, Belgium

Aarhus University Hospital

Aarhus, Denmark

Rigshospitalet Uni of Hospital of Copenhagen

Copenhagen, Denmark

Aou Policlinico S. Orsola-Malpighi

Bologna, Italy

Fondazione Irccs Istituto Nazionale Dei Tumori

Milan, Italy

Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore

Rome, Italy

Centro Ricerche Cliniche Di Verona

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07195916

Related Trials

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

NCT033661161 location

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

NCT054704911 location

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT0458892225 locations

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT0553614125 locations

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT0671013281 locations